Penciclovir

Penciclovir
Clinical data
Pronunciation/ˌpɛnˈsaɪkloʊˌvɪər/
Trade namesDenavir
AHFS/Drugs.comMonograph
MedlinePlusa697027
License data
Pregnancy
category
  • AU: B1
Routes of
administration
Topical
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability1.5% (oral), negligible (topical)
Protein binding<20%
MetabolismViral thymidine kinase
Elimination half-life2.2–2.3 hours
ExcretionKidney
Identifiers
  • 2-amino-9-[4-hydroxy-3-(hydroxymethyl)butyl]-1H-purin-6(9H)-one
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.189.687 Edit this at Wikidata
Chemical and physical data
FormulaC10H15N5O3
Molar mass253.262 g·mol−1
3D model (JSmol)
Melting point275 to 277 °C (527 to 531 °F)
  • O=C2/N=C(\Nc1n(cnc12)CCC(CO)CO)N
  • InChI=1S/C10H15N5O3/c11-10-13-8-7(9(18)14-10)12-5-15(8)2-1-6(3-16)4-17/h5-6,16-17H,1-4H2,(H3,11,13,14,18) checkY
  • Key:JNTOCHDNEULJHD-UHFFFAOYSA-N checkY
  (verify)

Penciclovir is a guanosine analogue antiviral medication used for the treatment of various herpesvirus infections. It is a nucleoside analogue which exhibits low toxicity and good selectivity. It is used as a topical treatment. It is sold under the brand name Denavir among others.

Penciclovir was approved for medical use in 1996.

Medical use

In herpes labialis, the duration of healing, pain and detectable virus is reduced by up to one day, compared with the total duration of 2–3 weeks of disease presentation.

Mechanism of action

Penciclovir is inactive in its initial form. In herpesvirus-infected cells, viral thymidine kinase phosphorylates penciclovir to penciclovir monophosphate; this first phosphorylation step is the rate-limiting step in its activation. Cellular kinases then phosphorylate penciclovir monophosphate to the diphosphate and subsequently to the active triphosphate, producing the active penciclovir triphosphate. Penciclovir triphosphate competitively inhibits viral DNA polymerase by competing with deoxyguanosine triphosphate (dGTP), thereby inhibiting viral DNA synthesis and replication.

The selectivity of penciclovir may be attributed to two factors. First, cellular thymidine kinases phosphorylate penciclovir only to a small extent, whereas viral thymidine kinase phosphorylates it much more efficiently, so the active triphosphate is present at much higher concentrations in virally infected cells than in uninfected cells. Second, penciclovir triphosphate inhibits viral DNA polymerase preferentially over cellular DNA polymerases with a much higher affinity than to human DNA polymerases. As a result of its preferential activation in infected cells and relatively low activity against cellular DNA polymerases, penciclovir has low cytotoxicity toward uninfected cells.

The structure and mode of action of penciclovir are very similar to that of other nucleoside analogues, such as the more widely used aciclovir. A difference between aciclovir and penciclovir is that the active triphosphate form of penciclovir persists within the cell for a much longer time than the activated form of aciclovir, so the concentration within the cell of penciclovir will be higher given equivalent cellular doses.[citation needed]